2024 ICD-10-CM Diagnosis Code T45.7X6A

Underdosing of anticoagulant antagonist, vitamin K and other coagulants, initial encounter

ICD-10-CM Code:
T45.7X6A
ICD-10 Code for:
Undrdose of anticoag antagonist, vit K and oth coag, init
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified
        (T45)

T45.7X6A is a billable diagnosis code used to specify a medical diagnosis of underdosing of anticoagulant antagonist, vitamin k and other coagulants, initial encounter. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024.

This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.

T45.7X6A is an initial encounter code, includes a 7th character and should be used while the patient is receiving active treatment for a condition like underdosing of anticoagulant antagonist vitamin k and other coagulants. According to ICD-10-CM Guidelines an "initial encounter" doesn't necessarily means "initial visit". The 7th character should be used when the patient is undergoing active treatment regardless if new or different providers saw the patient over the course of a treatment. The appropriate 7th character codes should also be used even if the patient delayed seeking treatment for a condition.

Clinical Classification

Clinical Information

  • Ethamsylate

    benzenesulfonate derivative used as a systemic hemostatic.
  • Hypoprothrombinemias

    absence or reduced levels of prothrombin in the blood.
  • Prothrombin

    a plasma protein that is the inactive precursor of thrombin. it is converted to thrombin by a prothrombin activator complex consisting of factor xa, factor v, phospholipid, and calcium ions. deficiency of prothrombin leads to hypoprothrombinemia.
  • Prothrombin Time

    clotting time of plasma recalcified in the presence of excess tissue thromboplastin. factors measured are fibrinogen; prothrombin; factor v; factor vii; and factor x. it is used for monitoring anticoagulant therapy with coumarins.
  • Thromboplastin

    constituent composed of protein and phospholipid that is widely distributed in many tissues. it serves as a cofactor with factor viia to activate factor x in the extrinsic pathway of blood coagulation.
  • Anticoagulants

    agents that prevent blood clotting.
  • Antithrombins

    endogenous factors and drugs that directly inhibit the action of thrombin, usually by blocking its enzymatic activity. they are distinguished from indirect thrombin inhibitors, such as heparin, which act by enhancing the inhibitory effects of antithrombins.
  • Carboxypeptidase B2

    a carboxypeptidase that removes c-terminal lysine or arginine from peptides and proteins. carboxypeptidase b2 (cpb2) is released into the circulation as a proenzyme which is activated by the thrombin-thrombomodulin complex. activated cpb2 is involved in modulating a variety of processes by cleaving and inactivating various circulating proteins and peptides that are its substrates including fibrin; kinins; and anaphylatoxins.
  • Factor VIIIa

    activated form of factor viii. the b-domain of factor viii is proteolytically cleaved by thrombin to form factor viiia. factor viiia exists as a non-covalent dimer in a metal-linked (probably calcium) complex and functions as a cofactor in the enzymatic activation of factor x by factor ixa. factor viiia is similar in structure and generation to factor va.
  • Receptors, Thrombin

    a family of proteinase-activated receptors that are specific for thrombin. they are found primarily on platelets and on endothelial cells. activation of thrombin receptors occurs through the proteolytic action of thrombin, which cleaves the n-terminal peptide from the receptor to reveal a new n-terminal peptide that is a cryptic ligand for the receptor. the receptors signal through heterotrimeric gtp-binding proteins. small synthetic peptides that contain the unmasked n-terminal peptide sequence can also activate the receptor in the absence of proteolytic activity.
  • Thrombin

    an enzyme formed from prothrombin that converts fibrinogen to fibrin.
  • Thrombin Time

    clotting time of plasma mixed with a thrombin solution. it is a measure of the conversion of fibrinogen to fibrin, which is prolonged by afibrinogenemia, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, or heparin. batroxobin, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin.
  • Factor VIII

    factor viii of blood coagulation. antihemophilic factor that is part of the factor viii/von willebrand factor complex. factor viii is produced in the liver and acts in the intrinsic pathway of blood coagulation. it serves as a cofactor in factor x activation and this action is markedly enhanced by small amounts of thrombin.
  • Factor XI

    stable blood coagulation factor involved in the intrinsic pathway. the activated form xia activates factor ix to ixa. deficiency of factor xi is often called hemophilia c.
  • Partial Thromboplastin Time

    the time required for the appearance of fibrin strands following the mixing of plasma with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). it is a test of the intrinsic pathway (factors viii, ix, xi, and xii) and the common pathway (fibrinogen, prothrombin, factors v and x) of blood coagulation. it is used as a screening test and to monitor heparin therapy.

Coding Guidelines

Underdosing refers to taking less of a medication than is prescribed by a provider or a manufacturer's instruction. Codes for underdosing should never be assigned as principal or first-listed codes. If a patient has a relapse or exacerbation of the medical condition for which the drug is prescribed because of the reduction in dose, then the medical condition itself should be coded.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified (T45). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:

  • Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Convert T45.7X6A to ICD-9-CM

  • ICD-9-CM Code: -
    No Map Flag -

Table of Drugs and Chemicals

The parent code T45.7X6 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
AcetomenaphthoneT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
Antiheparin drugT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
Coagulant NECT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
CotarnineT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
CytozymeT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
EtamsylateT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
EthamsylateT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
GelfoamT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
Hexadimethrine (bromide)T45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
MenadiolT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
Menadiol
  »sodium sulfate
T45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
MenadioneT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
Menadione
  »sodium bisulfite
T45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
MenaphthoneT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
MenaquinoneT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
MenatetrenoneT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
PhylloquinoneT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
PhytomenadioneT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
PhytonadioneT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
Protamine sulfateT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
Protamine sulfate
  »zinc insulin
T45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
ProthrombinT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
Prothrombin
  »activator
T45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
Prothrombin
  »synthesis inhibitor
T45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
Russel's viper veninT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
Sponge, absorbable (gelatin)T45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
ThrombinT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6
ThromboplastinT45.7X1T45.7X2T45.7X3T45.7X4T45.7X5T45.7X6

Patient Education


Medication Errors

Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:

  • Knowing your medicines. When you get a prescription, ask the name of the medicine and check to make sure that the pharmacy gave you the right medicine. Make sure that you understand how often you should take the medicine and how long you should take it.
  • Keeping a list of medicines.
    • Write down all of the medicines that you are taking, including the names of your medicines, how much you take, and when you take them. Make sure to include any over-the-counter medicines, vitamins, supplements, and herbs that you take.
    • List the medicines that you are allergic to or that have caused you problems in the past.
    • Take this list with you every time you see a health care provider.
  • Reading medicine labels and following the directions. Don't just rely on your memory - read the medication label every time. Be especially careful when giving medicines to children.
  • Asking questions. If you don't know the answers to these questions, ask your health care provider or pharmacist:
    • Why am I taking this medicine?
    • What are the common side effects?
    • What should I do if I have side effects?
    • When should I stop this medicine?
    • Can I take this medicine with the other medicines and supplements on my list?
    • Do I need to avoid certain foods or alcohol while taking this medicine?

Food and Drug Administration


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.